An observational study in Chronic Nonspecific Low Back Pain, sponsored by Mardin Artuklu University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Mardin Artuklu University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 295 studies in Low Back Pain with a site in Turkey — 63 open to participants now, 73 under way, none of them phase 3. Low Back Pain · Turkey.
Among the 295 studies in Low Back Pain with a site in Turkey, this one is the 16th largest by planned enrollment of the 83 observational ones that give a count, is one of 38 that started in 2026, is one of 83 observational ones, reaches primary completion later than 69 of the 72 other live ones, and was the 287th registered.
2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.
Browse Low Back Pain studies →63 of the 295 studies in Low Back Pain with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul Medipol University Hospital · Sites in Turkey
Ages 45–65 · Women only
Uskudar University · Sites in Turkey
Ages 18–45
Marmara University · Sites in Turkey
Ages 18–65
Istinye University · Sites in Turkey
Ages 18–65
Gaziosmanpasa Research and Education Hospital · Sites in Turkey
Ages 18–75
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
295 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 4 5
First in 2012; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 100 across 484 observational studies indexed under Low Back Pain.
Median enrollment 50 across the 212 interventional studies, 107 across the 83 observational. Of the 197 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 295 has an industry lead sponsor. The 10 most frequent:
Mardin Artuklu University is the lead sponsor of 34 studies on the registry; 15 are open to participants now.
Mardin Artuklu University has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
15 of the studies in Low Back Pain with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712406Gaziosmanpasa Research and Education HospitalUltrasound-Guided Proximal Superior Cluneal Nerve Block for Superior Cluneal Nerve Entrapment | 2026-11 |
| NCT07700589Istanbul Aydın UniversityComparison of Traditional, Synchronous, and Asynchronous Telerehabilitation in Office Workers With Chronic Nonspecific Low Back Pain | 2026-11-30 |
| NCT07809685Halic UniversityFactors Associated With Disability in Postpartum Lumbopelvic Pain | 2026-12-01 |
| NCT07856498Istanbul Medipol University HospitalPain Catastrophizing, Fear of Movement, and Physical Activity in Postmenopausal Women With Chronic Low Back Pain | 2026-12-01 |
| NCT07760103Uskudar UniversityCore Endurance Versus Segmental Stabilization Exercise in Recreational Athletes With Low Back Pain | 2026-12-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 295 studies in Low Back Pain with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study will examine whether signs of increased sensitivity in the nervous system at the beginning of the study are associated with short-term clinical outcomes in adults with chronic nonspecific low back pain. Approximately 180 participants will complete questionnaires about central sensitization, disability, pain, anxiety, and depression at the beginning of the study.
After 6 weeks, disability, pain, and the participant's overall perception of change will be assessed again. The researchers will evaluate whether the initial level of central sensitization is associated with meaningful improvement in disability and perceived treatment benefit. Participants will not be assigned to a treatment as part of this study and will continue to receive routine clinical care.
Background: Chronic nonspecific low back pain may have different clinical outcomes among patients. These differences cannot always be explained by structural findings. Central sensitization may be one of the factors related to treatment outcomes.
Objective: This study aims to investigate whether the baseline Central Sensitization Inventory (CSI) score can predict short-term clinical improvement and perceived treatment benefit in patients with chronic nonspecific low back pain.
Method: This prospective observational study will include 180 adults with chronic nonspecific low back pain. At baseline, the CSI, Oswestry Disability Index (ODI), Visual Analog Scale for pain, and Hospital Anxiety and Depression Scale will be completed. After 6 weeks of routine clinical care, the ODI, pain score, and Global Rating of Change will be evaluated again. A decrease of at least 30% in the ODI score will be accepted as clinically meaningful improvement. The relationship between the baseline CSI score and clinical outcomes at 6 weeks will be analyzed.
Adults aged 18-65 years with chronic nonspecific low back pain lasting for at least 3 months will be recruited from the Physical Medicine and Rehabilitation outpatient clinic of Mardin Training and Research Hospital. Participants will receive routine clinical care and will be evaluated at baseline and after 6 weeks. No healthy control group will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18-65 years with chronic nonspecific low back pain will be evaluated at baseline and followed for 6 weeks. Participants will receive routine clinical care determined by their treating physician. No treatment or intervention will be assigned by the study protocol. Baseline central sensitization symptoms will be evaluated in relation to disability, pain, and perceived improvement at 6 weeks.
Clinically Meaningful Improvement in the Oswestry Disability Index
The proportion of participants who achieve a reduction of at least 30% in the Oswestry Disability Index (ODI) score from baseline. The ODI ranges from 0 to 100, with higher scores indicating greater disability.
Time frame: Baseline to 6 weeks
Change in the Oswestry Disability Index Score
Change in the Oswestry Disability Index (ODI) score from baseline to 6 weeks. The ODI ranges from 0 to 100, with higher scores indicating greater disability. A greater reduction indicates greater improvement in disability.
Time frame: Baseline to 6 weeks
Change in Pain Intensity
Change in pain intensity measured using a 0-10 Visual Analog Scale from baseline to 6 weeks. A score of 0 indicates no pain, and a score of 10 indicates the worst possible pain. A greater reduction indicates greater improvement in pain.
Time frame: Baseline to 6 weeks
Patient-Perceived Improvement
Patient-perceived change in overall clinical status will be assessed using the Global Rating of Change scale at 6 weeks. Participants will report whether their condition has improved, remained unchanged, or worsened compared with baseline. The responses will be classified as perceived treatment benefit or no perceived treatment benefit according to the prespecified study criteria.
Time frame: At 6 weeks
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 177 non-industry observational studies under Low Back Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 12 months is below that.
Counting every sponsor, half of 187 studies reached it within 24 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mardin Artuklu University